Rigel Pharmaceutical Inc. buy Quitte
Start price
04.01.17
/
50%
€2.26
Target price
08.03.17
€2.62
Performance (%)
17.60%
End price
08.03.17
€2.65
Summary
This prediction ended on 08.03.17 with a price of €2.65. The prediction had a final performance of 17.60%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Rigel Pharmaceutical Inc. | -4.927% | -4.927% | -28.473% | -71.223% |
| iShares Core DAX® | 1.851% | 5.158% | 17.711% | 19.954% |
| iShares Nasdaq 100 | 1.573% | 2.589% | 39.053% | 56.636% |
| iShares Nikkei 225® | -0.412% | -2.857% | 13.501% | 7.721% |
| iShares S&P 500 | 1.128% | 2.485% | 29.871% | 47.507% |
Comments by Quitte for this prediction
In the thread Rigel Pharmaceutical Inc. diskutieren
Rheumatoide Arthritis
nachdem Fostamatinib in Phase II gescheitert ist und das Unternehmen die Entwicklung aber nicht ab acta gelegt hat, rechne ich mir Chancen aus